GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and inf…
Industry Peers
Diagnostics & Research| Headline | Source | Time |
|---|---|---|
This week | ||
 Can GENEDX HOLDINGS (WGS) Run Higher on Rising Earnings Estimates? GeneDx Holdings Corp. (WGS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions. | ||
Older | ||
 GeneDx (WGS) Q2 2026 Earnings Call Transcript Genomic testing volume surged 32% as profitability returned ahead of schedule. | ||
 GeneDx Holdings (WGS) Is Up 18.4% After Reaffirming 2026 Outlook And Raising Equity From Blackstone In early August 2026, GeneDx Holdings Corp. reported second-quarter revenue of US$114.44 million with a net loss of US$17.74 million, reaffirmed its full-year 2026 revenue outlook, and announced a private placement of 81,967 Class A shares at US$61.00 each with participation from a Blackstone affiliate. The combination of higher revenue alongside a shift from profit to loss, together with fresh equity capital from a major institutional investor, gives investors new information on GeneDx’s... | ||
 GeneDx Holdings Corp. Q2 2026 Earnings Call Summary Moby summary of GeneDx Holdings Corp.'s Q2 2026 earnings call | ||
GeneDx Holdings Corp (WGS) (Q2 2026) Earnings Call Highlights: Record Volume and Early ... GeneDx returns to profitability ahead of schedule, driven by 32% exome and genome volume growth and expanded commercial coverage. | ||
 GeneDx Q2 Earnings Call Highlights GeneDx (NASDAQ:WGS) reported second-quarter revenue of $114.4 million, above its prior guidance, as exome and genome testing volume reached a quarterly record of more than 30,000 tests. The company also returned to adjusted profitability one quarter earlier than previously expected, while maintainin | ||
 GeneDx Holdings Corp. (WGS) Q2 Earnings and Revenues Surpass Estimates GENEDX HOLDINGS (WGS) delivered earnings and revenue surprises of +105.26% and +4.32%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 GeneDx Holdings Corp. (WGS) Slid as Revenue Fell Short of Expectations Fred Alger Management, an investment management company, released its “Alger Small Cap Focus Fund” second-quarter 2026 investor letter. A copy of the letter can be downloaded here. U.S. equities experienced a strong recovery in Q2 2026, with the S&P 500 Index gaining 15.2%, marking its best quarter since 2020. A ceasefire between the United States […] | IInsider Monkey | |
 GeneDx Holdings Corp. (WGS) Fell Following a Significant Cut in 2026 Guidance Polen Capital, an investment management company, released its second-quarter 2026 investor letter for “Polen 5Perspectives Small Growth Strategy”. A copy of the letter can be downloaded here. Polen 5Perspectives Small Growth Composite Portfolio returned 33.22% gross and 32.83% net of fees, respectively, in the second quarter of 2026, compared to the 25.71% return of the […] | IInsider Monkey | |